-
Featured
Cromolyn Sodium Provides Neuroprotection in Animal Model of ALS
Building on similar research in Alzheimer's disease, researchers at Massachusetts General Hospital demonstrated that treatment with cromolyn sodium delayed disease onset and was neuroprotective in a mouse model of amyotrophic lateral sclerosis by decreasing the inflammatory response.
-
Featured
Case of Resistance to Autosomal Dominant Alzheimer's Disease Suggests New Direction for Treatment
A woman with autosomal dominant Alzheimer's disease had very late onset of mild cognitive impairment, apparently because she was homozygous for the APOE3 Christchurch mutation.
-
Featured
Patterns of Neural Network Degradation Differ in Alzheimer's Disease and Normal Aging
Functional MRI may someday be able to distinguish the neurodegenerative changes related to early Alzheimer's disease from those of normal aging.
-
Toward a Precision Medicine Approach to Deep Brain Stimulation
Victoria Peterson, PhD, Mark Richardson, MD, PhD, and colleagues showed that applying spatial filters improves machine-learning analysis of movement-related oscillations on invasive cortical and subcortical recordings, an important step toward providing individualized therapy with adaptive deep brain stimulation.
-
Tofersen Lowers Disease Markers, Slowing Progression for SOD1-Mutated ALS in Phase 3 Trial
Merit E. Cudkowicz, MD, MSc, and colleagues report that in a phase 3 randomized trial, patients with faster-progressing SOD1-mutated amyotrophic lateral sclerosis who received tofersen showed greater reductions in SOD1 than the placebo group, but the primary endpoint of change in ALS-related function was not met.
-
Functional MRI of Locus Coeruleus Might Detect Risk of Alzheimer's Disease
Massachusetts General Hospital researchers have associated lower novelty-related locus coeruleus (LC) function with steeper amyloid-related cognitive decline in clinically normal older adults, suggesting functional MRI of the LC might distinguish between individuals at risk of vs. resistant to Alzheimer's disease.
Neurodegenerative Disease Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
The Future of Neurosurgery and Neuroscience at Mass General: Q&A With Bob S. Carter, MD, PhD
-
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Novel Target Identified for Treatment of ALS
-
Jeffrey S. Schweitzer, MD, PhD
Neurosurgeon
Recent Article
Patient-derived Dopamine Neurons Show Promise in Parkinson's Treatment
-
Joel A. Salinas, MD, MSc, MBA
Chief, McCance Brain Health Unit
Recent Article
MicroRNA From Whole Blood May Be Stroke Biomarker, Therapeutic Target
-
Jonathan Rosand, MD
Co-Director, Henry and Allison McCance Center for Brain Health, Chief, Division of Neurocritical Care and Emergency Neurology, Medical Director, Neuroscience Intensive Care Unit
Recent Article
Special Report: The Bugher Network in Hemorrhagic Stroke
-
Keith A. Johnson, MD
Radiologist
Recent Article
Tau PET Imaging May Help Identify People with Pre-symptomatic Alzheimer’s Disease
-
Todd M. Herrington, MD, PhD
Director, Deep Brain Stimulation Program, Massachusetts General Hospital
Recent Article
Patient-derived Dopamine Neurons Show Promise in Parkinson's Treatment
-
Yakeel T. Quiroz-Gaviria, PhD
Associate Professor, Harvard Medical School, Director, Familial Dementia Neuroimaging Lab, Director, Multicultural Alzheimer's Prevention Program, Massachusetts General Hospital, Paul B. and Sandra M. Edgerley MGH Research Scholar 2020-2025
Recent Article
MRI Feature Is Marker of Disease Progression in Preclinical Autosomal Dominant Alzheimer's Disease
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.